Cellular Biomedicine Group, Inc.
CBMG
CBMG was delisted on the 19th of February, 2021.
45 hedge funds and large institutions have $52.2M invested in Cellular Biomedicine Group, Inc. in 2020 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 9 reducing their positions, and 6 closing their positions.
89% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 9
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
10% more funds holding
Funds holding: 41 → 45 (+4)
22% less capital invested
Capital invested by funds: $67.3M → $52.2M (-$15.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$2.89M |
| 2 |
MAM
Martingale Asset Management
Boston,
Massachusetts
|
+$1.24M |
| 3 |
Russell Investments Group
London,
United Kingdom
|
+$921K |
| 4 |
BlackRock
New York
|
+$774K |
| 5 |
Bessemer Group
Woodbridge,
New Jersey
|
+$698K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NAMA
Nikko Asset Management Americas
New York
|
-$7.54M |
| 2 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$7.54M |
| 3 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$5.94M |
| 4 |
Man Group
London,
United Kingdom
|
-$464K |
| 5 |
MIM
MetLife Investment Management
Whippany,
New Jersey
|
-$98.1K |
CBMG Hedge Fund Activity: Q2 2020 in Review
45 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Cellular Biomedicine Group, Inc. (CBMG) for Q2 2020, worth a combined $52.2M — down 22% from $67.3M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CBMG positions and 6 closed out — a net gain of 4 holders — while 17 added to existing stakes and 9 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $2.89M. The largest seller was Nikko Asset Management Americas, exiting entirely with an estimated $7.54M sold.
- 45 institutional investors held Cellular Biomedicine Group, Inc. (CBMG) as of Q2 2020, up from 41 in Q1 2020.
- Funds reported $52.2M of Cellular Biomedicine Group, Inc. stock for Q2 2020, down 22% quarter-over-quarter.
- 10 funds opened new Cellular Biomedicine Group, Inc. positions in Q2 2020 and 6 closed out, a net change of +4 holders.
- The largest Cellular Biomedicine Group, Inc. buyer in Q2 2020 was ARK Investment Management, an estimated $2.89M added.
- The largest Cellular Biomedicine Group, Inc. seller in Q2 2020 was Nikko Asset Management Americas, an estimated $7.54M sold.
Based on aggregated 13F filings for Q2 2020.